New hope for rare, aggressive breast cancer: triple drug combo shows promise
NCT ID NCT03202316
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study tests two drug combinations for people with inflammatory breast cancer that has come back or spread. One group gets three drugs (atezolizumab, cobimetinib, eribulin) and the other gets two (atezolizumab and eribulin). The goal is to see if these combos shrink tumors. About 37 adults with this rare, fast-growing cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BREAST INFLAMMATORY CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.